Research programme: synthetic antimicrobial peptidomimetics - Lytix Biopharma

Drug Profile

Research programme: synthetic antimicrobial peptidomimetics - Lytix Biopharma

Alternative Names: LTX100; LTX200

Latest Information Update: 04 Feb 2011

Price : $50

At a glance

  • Originator Lytix Biopharma
  • Class Amino acids peptides and proteins
  • Mechanism of Action Cell membrane modulators; Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Bacterial infections; Mycoses

Highest Development Phases

  • Preclinical Bacterial infections; Mycoses

Most Recent Events

  • 04 Feb 2011 Research programme: synthetic antimicrobial peptidomimetics - Lytix Biopharma is available for licensing as of 23 Oct 2006. http://www.lytixbiopharma.com
  • 15 Sep 2009 Antimicrobial data from in vitro studies in Bacterial infections presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009) ,,,,
  • 28 Oct 2008 Antimicrobial data from a preclinical study in Bacterial infections presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America (ICAAC/IDSA-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top